Abstract
A double-blind placebo-controlled dose-response trial of nebivolol, a cardioselective beta-blocking drug which also induces endothelium-dependent dilatation via nitric oxide, has been performed. Nebivolol reduced blood pressure (BP) in a dose dependent way, and was shown to be effective given once daily, without appreciable differences between peak and trough drug levels. There was no postural component to the BP fall. There was no clear inferiority of efficacy in black patients. A single daily dose of 5 mg was appropriate, with no evident advantage at 10 mg. The drug was well tolerated, even at 10 mg daily. BP control was achieved largely in the absence of typical side effects of beta-blockade. The combination of properties of nebivolol renders it an attractive addition to the antihypertensive repertoire.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Nueten, L., Dupont, A., Vertommen, C. et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 11, 139–144 (1997). https://doi.org/10.1038/sj.jhh.1000392
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000392
Keywords
This article is cited by
-
Nebivolol for the Treatment of Arrhythmias: a Narrative Review
Current Treatment Options in Cardiovascular Medicine (2022)
-
Aortic elastic properties
Herz (2013)
-
Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension
Journal of Human Hypertension (2010)
-
Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients
Advances in Therapy (2010)
-
The vasodilatory beta-blockers
Current Hypertension Reports (2007)